At the ASCO 2019 annual meeting, Ramon Andrade de Mello discusses the promise of immunotherapies in oesophageal and gastric cancer. Highlighting the need to understand the tumor microenvironment to allow identification of biomarkers to appropriately select the best immune checkpoint inhibitors he also considers the role of combination therapy in improving overall outcomes.
Questions
1. What are the limitations of current immunotherapies in oesophageal and gastric cancer? (0:03)
2. How can we optimise the delivery of immunotherapy to overcome immunosuppression in the tumour microenvironment? (1:38)
3. What combined immunotherapy approaches appear most promising for oesophageal and gastric cancer? (2:51)
4. How can we select patients who are most likely to respond to combined immunotherapy approaches? (3:55)
5. What novel approaches are likely to emerge in the near future? (5:03)
Speaker disclosure: Ramon Andrade de Mello has received speaker honoraria from Novartis and AstraZeneca, an educational grant from Merck & Co and participated in advisory boards for MSD, Pfizer and Zodiac.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
